Epidemiology of viral hepatitis and HIV co-infection.

Worldwide, hepatitis B virus (HBV) accounts for an estimated 370 million chronic infections, hepatitis C virus (HCV) for an estimated 130 million, and HIV for an estimated 40 million. In HIV-infected persons, an estimated 2-4 million have chronic HBV co-infection and 4-5 million have HCV co-infection. HBV, HCV and HIV share common routes of transmission, but they differ in their prevalence by geographic region and the efficiency by which certain types of exposures transmit them. Among HIV-positive persons studied from Western Europe and the USA, chronic HBV infection has been found in 6-14% overall, including 4-6% of heterosexuals, 9-17% of men who have sex with men (MSM), and 7-10% of injection drug users. HCV infection has been found in 25-30% of HIV-positive persons overall; 72-95% of injection drug users, 1-12% of MSM and 9-27% of heterosexuals. The characteristics of HIV infected persons differ according to the co-infecting hepatitis virus, their epidemiologic patterns may change over time, and surveillance systems are needed to monitor their infection patterns in order to ensure that prevention measures are targeted appropriately.

[1]  C. Pedersen,et al.  Molecular epidemiology of hepatitis B virus infections in Denmark. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  R. Chung,et al.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  A. Osterhaus,et al.  Molecular epidemiology of hepatitis B virus in Amsterdam 1992–1997 * , 2002, Journal of medical virology.

[4]  B. Wallace,et al.  Deja vu: nosocomial hepatitis B virus transmission and fingerstick monitoring. , 1998, The American journal of medicine.

[5]  S. King,et al.  Mother‐to‐infant transmission of hepatitis C virus , 2001, Hepatology.

[6]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[7]  Y. Hutin,et al.  The global burden of disease attributable to contaminated injections given in health care settings , 2004, International journal of STD & AIDS.

[8]  M. Favero,et al.  SURVIVAL OF HEPATITIS B VIRUS AFTER DRYING AND STORAGE FOR ONE WEEK , 1981, The Lancet.

[9]  A. Haverich,et al.  Nosocomial hepatitis B virus infections in cardiac transplant recipients transmitted during transvenous endomyocardial biopsy. , 1994, The Journal of hospital infection.

[10]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[11]  W. Edmunds,et al.  Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  H. O'neill,et al.  Hepatitis delta virus infection in Northern Ireland 1970-1989. , 1989, The Ulster medical journal.

[13]  N. Beeching,et al.  Hepatitis B prevalence among Somali households in Liverpool , 2002, Archives of Disease in Childhood.

[14]  P. Weinbreck,et al.  [Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus]. , 1997, Pathologie-biologie.

[15]  Schmit,et al.  Long‐term stability of human immunodeficiency virus viral load and infectivity in whole blood , 1999, European journal of clinical investigation.

[16]  J. Perz.  Estimated Global Prevalence of Hepatitis C Virus Infection , 2004 .

[17]  A. Zanetti,et al.  Mother-to-infant transmission of hepatitis C virus , 1995, The Lancet.

[18]  M. J. van de Laar,et al.  The importance of imported infections in maintaining hepatitis B in The Netherlands , 2004, Epidemiology and Infection.

[19]  M. Alter,et al.  Prevention of spread of hepatitis C , 2002, Hepatology.

[20]  H. Margolis,et al.  Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. , 2002, The Journal of infectious diseases.

[21]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[22]  S. Kleinman,et al.  Current and emerging infectious risks of blood transfusions. , 2003, JAMA.

[23]  M. Alter,et al.  Epidemiology of hepatitis B in Europe and worldwide. , 2003, Journal of hepatology.

[24]  J. Duchin,et al.  Sharing of drug preparation equipment as a risk factor for hepatitis C. , 2001, American journal of public health.

[25]  P. Lopalco,et al.  Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[26]  J. Heptonstall,et al.  Hepatitis B outbreak in a drug trials unit: investigation and recommendations. , 1994, Communicable disease report. CDR review.

[27]  M. Sulkowski,et al.  Hepatitis C in the HIV-Infected Person , 2003, Annals of Internal Medicine.

[28]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[29]  E. Ribera,et al.  Hepatitis C virus and human immunodeficiency virus coinfection in Spain. , 2003, The Journal of infection.

[30]  D. Dhumeaux,et al.  An outbreak of hepatitis B in an endocrinology unit traced to a capillary-blood-sampling device. , 1990, New England Journal of Medicine.

[31]  R. Garfein,et al.  Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. , 2002, American journal of epidemiology.